ScreenerHero

EQEquillium, Inc.

NAS · US · Healthcare · Biotechnology · equilliumbio.com
2.310USD-0.86%Mkt Cap: 146.47M $P/E: —

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR m…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap146.47M $
Enterprise Value87.36M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.40M $
Revenue/Share—
Last Price2.310 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.69
PEG—
EV/EBITDA-4.55
EV/Revenue—
P/S—
P/B2.57
EPS (TTM)-0.09
EPS (Forward)-0.23
52W Range
0.760056% of range3.540
52W High3.540 USD
52W Low0.7600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-78.32%
ROA-70.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.75M $
CapEx (TTM)48.00K $
FCF Margin—
FCF Yield-10.33%
Net Debt-56.58M $
Net Debt/EBITDA2.95
Balance Sheet
Debt/Equity0.03
Current Ratio23.40
Quick Ratio23.07
Book Value/Sh0.8830 USD
Cash/Share0.9020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.556 USD
Upside (mean)+270.4%
Target Range4.000 USD – 20.00 USD
$4.000+270.4% to mean$20.00
# Analysts9
Ownership
Shares Out.63.41M
Float35.69M
Insiders16.00%
Institutions65.76%
Short Interest
Short Ratio5.6d
Short % Float9.93%
Short % Out.8.57%
Shares Short5.42M
Short (prev mo.)5.11M
Technical
SMA 502.612 (-11.5%)
SMA 2001.925 (+20.0%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)626.08K
Avg Vol (10d)531.63K
Technical Indicators
RSI (14)47.4
MACD-0.0843
MACD Signal-0.1179
MACD Hist.+0.0335
BB Upper2.600 USD
BB Middle2.287 USD
BB Lower1.973 USD
BB Width27.40%
ATR (14)0.2186 USD
Vol Ratio (20d)1.10x